Quest Diagnostics (DGX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Apr, 2026Executive summary
Annual meeting scheduled for May 20, 2026, with voting available online or in person.
Shareholders are encouraged to review proxy materials and vote on key proposals by May 19, 2026.
Voting matters and shareholder proposals
Election of eleven directors, each recommended by the board.
Advisory vote on executive officer compensation for 2026, with board recommending approval.
Ratification of the appointment of the independent registered public accounting firm for 2026, recommended by the board.
Stockholder proposal regarding an independent board chairman, with board recommending a vote against.
Board of directors and corporate governance
Eleven nominees for the board, including a mix of experienced executives and industry professionals.
Board recommends all nominees for election.
Latest events from Quest Diagnostics
- Q2 2026 revenue up 10.2%, adjusted EPS up 19.1%, and full-year guidance raised.DGX
Q2 202623 Jul 2026 - Q1 2025 revenue up 12.1%, adjusted EPS up 8.3%, net income up 13.2%.DGX
Q1 202523 Jul 2026 - Multi-cancer early detection is poised to transform cancer care through innovation, partnerships, and policy advocacy.DGX
7th Annual Healthcare Symposium15 Jul 2026 - Specialty test growth, AI adoption, and new partnerships drive volume and margin expansion.DGX
Leerink Global Healthcare Conference 20269 Jul 2026 - Q4 and 2024 saw strong growth, with 2025 guidance projecting further expansion and investment.DGX
Q4 20248 Jul 2026 - Q3 revenue up 8.5% and guidance raised, driven by acquisitions and advanced diagnostics.DGX
Q3 20248 Jul 2026 - Q2 revenue up 2.5%, base business nearly 4%, and guidance raised on acquisitions and productivity.DGX
Q2 20248 Jul 2026 - Targets 4-5% revenue and 7-9% EPS CAGR, fueled by innovation, acquisitions, and productivity.DGX
Investor Day 20258 Jul 2026 - Q1 2026 saw strong organic growth, higher EPS, and raised full-year guidance.DGX
Q1 202623 Apr 2026 - Double-digit revenue and EPS growth in 2025, with strong 2026 outlook and higher dividend.DGX
Q4 202513 Apr 2026